Check 35,000+ stocks against 26 valuation models and 37 quality factors
Data-driven stock valuation
Which stocks are undervalued right now? Check free
Discover now →
Imerys S.A (IMYSF) fair value: what the stock is really worth
As of Sep 25, 2026: fair value of Imerys S.A $9.55, price $25.59, upside -62.7%, quality 43 out of 100. Calculated from audited financials with 26 valuation models and 37 quality factors, updated daily.
- Fair value above price? No
- Good quality? No
- Add to watchlist
IS
Broad data
Sep 24, 2026
Broad data
Sep 24, 2026
Imerys S.A
IMYSF · USWeakest SetupStrongly overvalued and low quality.
!Fair value $9.55 · Strongly overvalued (−62.7%)
!Quality 43/100
!Weak Growth (revenue 5y −2.3 %/yr)
!Loss-making · -12.9% net margin (TTM)
✓Moderate debt · generates free cash flow
!Narrow moat 21/100
!The models disagree: range $9.55 to $23.44
What runs behind every stock
26
valuation models
8 families, DCF to NCAV
37
quality factors
margins, balance sheet, cashflow, debt
6
AI factors
moat, what no ratio measures
2,000+
data points
verified, per stock, median
69 individual criteria per stock, every one traceable See the method →
Price vs Fair Value
White line = price, green steps = our fair value per fiscal year. As of Sep 24, 2026.
How to read this chart
60‑month range $16.13 – $51.21 · fair‑value band $9.55 – $23.44 · the $25.59 price screens above the $9.55 fair value. As of Sep 24, 2026.
Company profile
Imerys S.A. engages in the supply of specialty minerals for various industries across Europe, the Middle East, Africa, Asia Pacific, and America.
Show more
Imerys S.A. engages in the supply of specialty minerals for various industries across Europe, the Middle East, Africa, Asia Pacific, and America. The company offers performance minerals, such as additives for plastics, paints and coatings, filtration and life sciences, ceramics, and building products; specialty minerals used as processing aids for extreme work conditions, including refractory, foundry, abrasives, and building chemistry; and graphite and carbon minerals for energy transition and mobile energy markets. It also provides minerals, such as andalusite, ball clay, bentonite, calcium carbonate, carbon black, chamotte, diatomite, feldspar, fused alumina, graphite, halloysite, kaolin, lithium, mica, moler, mullite, perlite, quartz, talc, zeolite, zirconia, and wollastonite. The company serves various markets, such as abrasives, advanced ceramics, animal care, batteries and fuel cells, building materials, ceramics, component manufacturing, cosmetics and personal care, crop production, food and beverage, health, pharmaceuticals and biotechnology, home care, infrastructure and utilities, investment casting, pulp and packaging, and rubber markets. The company was incorporated in 1880 and is headquartered in Paris, France. Imerys S.A. is a subsidiary of Belgian Securities BV.
Stock analysis
Imerys S.A (IMYSF) currently trades at $25.59, while our model-based Fair Value estimate is $9.55, 62.7% below the price, so the stock looks overvalued today.
Show more
Valuation
Bull case: the Asset-Based group reads highest at a median of $23.25 per share, and 3 of the 14 models we run sit above the $25.59 price.
Bear case: the Growth DCF group reads lowest at $4.28, and 11 of the 14 models stay below the price. Evidence for this calculation is high.
Scenario range: $9.55 (bear) to $23.44 (bull), the price of $25.59 sits above it. Bear and bull are the same models on cautious and optimistic assumptions, a range, not a price target.
Quality & growth
The Quality Score stands at 43/100 (below-average quality), in the Basic Materials sector.
Weak Growth: Revenue is shrinking: the last year, the last three and the last five years are all negative.
Imerys S.A reported revenue of €3.4B in FY2025 versus €4.4B in FY2021, a compound −6.3%/yr. Reported net income was −€409M in FY2025.
Key figures
Market cap $2.2B · P/E ratio 12.9 · P/S ratio 0.68 · EPS (TTM) $1.99 · Net margin −12.1% · Return on equity −13.9% · Return on assets (EBIT) 4.3% · Operating margin 5.5%.
Competitive moat
Our AI-assisted moat analysis scores the competitive advantage at 39 out of 100 (low confidence).
What moves the price
For context, the median of 10 Basic Materials peers we cover trades at −46% fair-value upside, at −63%, IMYSF screens richer than that median.
Fair Value models
Bear $9.55
Fair Value $9.55
Bull $23.44
Model ⓘEach model values the company its own way (discounted cash flow, earnings, assets, dividends). The fair value above is their evidence-weighted blend, not the output of a single model. Based on fiscal year 2025 figures (about 9 months old). Earnings retained since then ($1.50 per share) are deliberately not added.
Bear ⓘBear = the cautious scenario: the same model computed with conservative anchors (lower growth, margins and valuation multiples). Together with Bull it frames a plausible valuation range, not a price target.BaseBull ⓘBull = the optimistic scenario: the same model computed with favourable anchors (higher growth, margins and valuation multiples). Together with Bear it frames a plausible valuation range, not a price target. If a model's bull case is above four times its base value, the table shows that limit with a > sign (like the overall Bull above): beyond it no assumption holds.
Evidence ⓘEvidence = how well-backed THIS model's estimate is for this stock (0–100): how complete and reliable its input data are, and how well the model fits the company. The final Fair Value is an evidence-weighted blend, so better-evidenced models count more. Green ≥70, amber 50–69, grey below 50.
Highest evidence
FCF DCF
n/a
$3.76
>$15.04
77
Growth DCF
n/a
$4.28
$14.83
75
Owner Earnings
n/a
$6.78
$20.10
73
All 14 models by family
DCF Models
FCF DCF
n/a
$3.76
>$15.04
77
Owner Earnings
n/a
$6.78
$20.10
73
5Y Revenue Exit
n/a
$8.89
$23.18
69
5Y EBITDA Exit
$40.11
$79.94
$132.68
72
10Y Revenue Exit
n/a
$4.69
$12.38
64
10Y EBITDA Exit
$22.51
$47.63
$75.19
66
Dividend Discount
Gordon GGM
$14.45
$15.75
$17.71
69
DDM Multi-Stage
$14.45
$17.85
$22.50
67
Multiples
EV/EBIT
$5.82
$14.73
$23.65
61
EV/EBITDA
$83.72
$118.61
$153.49
67
EV/Revenue
$2.25
$12.18
$22.12
48
Asset-Based
NCAV (Graham)
$17.35
$23.25
$34.70
54
Growth DCF
Growth DCF
n/a
$4.28
$14.83
75
Rev-Margin DCF
n/a
$9.33
$21.84
69
Notify me when IMYSF reaches fair value
Put IMYSF on your watchlist. We get in touch as soon as price and fair value meet or the trend turns.
Set up alert →Quality Score breakdown
Overall quality
43/100
Of which business quality 41 · Market factors (momentum, volatility) 24
Profitability
20
Margins and returns on capital today
Quality Growth
29
Are margins and returns improving?
Cashflow
26
Earnings quality: real cash, not paper profit
Fin. Strength
34
Balance sheet, leverage, solvency risk
Investment
86
Disciplined investing over empire-building
Low Volatility
41
Calm price path (market factor)
Momentum
27
Price trend over the last 3–12 months (market factor)
52W Momentum
0
Distance to the 52-week high (market factor)
Net Issuance
82
Share count: buybacks or dilution?
Revenue & earnings trend
Growth Quality ⓘGrowth is valuable only when reinvestment earns attractive returns (Aswath Damodaran): sustainable growth depends on return on capital, reinvestment and efficiency. Basis: total company revenue over the periods shown on the cards (3Y/5Y/all years), not per share, so a merger can show up as a growth jump; per-share earnings growth is in the value-creation card.
18/100
Revenue is shrinking: the last year, the last three and the last five years are all negative.
Revenue growth 1 year
−6.1%
Revenue growth 3 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
−7.5%
Revenue growth 5 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
−2.3%
Start year 2020 (pandemic). Over 10 years: −1.9% a year
Revenue growth 11 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
−0.8%
’14
’15
’16
’17
’18
’19
’20
’21
’22
’23
’24
’25
Profit margin (trend) ⓘOperating margin then vs now, from reported annual statements. A falling margin after a boom year is the classic peak-earnings signal: the growth rate then leans on an inflated base.
7.8% (2020) → 5.6% (2025)
What shareholders gained per year ⓘWe only publish this rate when it is defensible. Reason: fiscal 2025 is a loss year, no rate is defined from a loss
not computed
Growth Forecast
A lot of optimism in the price
The price assumes more growth than the company has delivered so far and more than analysts expect.
What the price assumes ⓘThis turns our valuation around: instead of asking what the share is worth, it asks what growth the current price requires. It uses the cash the company keeps after all spending (free cash flow), the same discount rate as our models, five years of growth, then slowing evenly to 2 % a year by year ten. Compared with the analysts' sales forecasts extended to the same five years (at least three analysts, for context only, it does not enter the Fair Value): within 3 percentage points counts as "in line" (amber), below that little optimism (green), above that a lot of optimism (red).
+16.3%
Yearly growth needed for the next five years to justify today's price.
What forecasts expect ⓘAnalysts publish sales forecasts for the next two fiscal years. For the years after that, growth slows evenly to 2 % a year by year ten (2 % is the long-run rate our models use). Projected years are marked as such.
+2.3%
Yearly sales growth analysts expect, extended to five years.
After inflation (figures in EUR, euro area: IMF forecast 2.2% a year to 2030, 2.6% from 2016 to 2025) that is about +13.8% a year for the price and +0.1% for the forecasts.
Forecast 2026 (sales)+0.7%
Forecast 2027 (sales)+2.8%
Projected 2028 (sales)+2.7%
Projected 2029 (sales)+2.6%
Projected 2030 (sales)+2.5%
IMYSF screens overvalued: fair value 63% below the price. Compare with Linde plc →
Compare Imerys S.A with another stock
Price, fair value, quality and upside side by side.
Free, no sign-up
Context: sector, industry, market
- P/E, EV/EBITDA and margins by industry (reference tables)
- Undervalued stocks: US Stocks
- Valuation of the USA market
Values & ESG
Does this company touch areas you may want to avoid? The classification is inferred from sector and industry.
None of the checked exposures detected
Similar stocks
10 more Specialty Chemicals stocks, each showing price versus our Fair Value estimate.
| Stock | Price | Fair Value | vs Fair Value |
|---|---|---|---|
| Linde plc LIN | $474.65 | $441.72 | −7% |
| The Sherwin-Williams Company SHW | $330.44 | $151.68 | −54% |
| Ecolab Inc ECL | $274.58 | $96.56 | −65% |
| Air Products and Chemicals, Inc APD | $279.19 | $121.30 | −57% |
| Nan Ya Plastics Corporation 1303 | 238.00 TWD | 234.23 TWD | −2% |
| Givaudan SA GIVN | CHF 3,360 | CHF 1,527 | −55% |
| Sika AG SIKA | CHF 183.80 | CHF 98.89 | −46% |
| Wanhua Chemical Group 600309 | ¥69.45 | ¥68.03 | −2% |
| DSM-Firmenich AG DSFIR | CHF 92.30 | CHF 29.70 | −68% |
| Asian Paints Limited ASIANPAINT | ₹2,444 | ₹1,479 | −39% |
Explore undervalued stocks
More undervalued Basic Materials stocks →
All undervalued stocks
TechnologyFinancial ServicesHealthcareConsumer CyclicalConsumer DefensiveCommunication ServicesIndustrialsEnergyBasic MaterialsReal EstateUtilities Deeply Undervalued StocksUndervalued High-Quality StocksUndervalued Blue-Chip StocksUndervalued Small-Cap StocksUndervalued Dividend Stocks
Try a ready-made strategy
Pick a strategy and jump into the live analysis with that exact screen applied.
🥇 Backtested Best
🏆 Big Names
⭐ Top Rated
💎 Quality on Sale
🚀 Profitable Growth
🧊 Quality Compounders
💵 Dividend Stars
📈 Strong Momentum
📉 Fallen Angels
⚖️ Deeply Undervalued
🔍 Small-Cap Gems
🏰 Moat at a Fair Price
💼 Insider Buying
🎩 Buffett-Style Quality
📚 Peter Lynch GARP
🧮 Greenblatt Magic Formula
🛡️ Graham Defensive
Discover tools
Stock screenerFilter by region, size and sector
Compare toolTwo stocks side by side
Extrinsic Value Calculator…Calculator with industry benchmark
Peter Lynch Fair Value Formula &…Calculator with industry benchmark
Run the numbers yourself: free valuation calculators
Frequently asked questions
Is Imerys S.A (IMYSF) overvalued or undervalued?
As of Sep 24, 2026, our model estimates a fair value of $9.55 versus the last price from Sep 25, 2026 of $25.59, about −63% upside (overvalued).
What is the fair value of IMYSF?
Our model-based fair value for Imerys S.A is $9.55 (as of Sep 24, 2026), built from audited fundamentals. Last price (from Sep 25, 2026): $25.59.
What is the quality score of IMYSF?
Imerys S.A has a Quality Score of 43/100. It measures business quality (profitability, growth, cash flow, balance-sheet strength, investment discipline, share issuance). Market factors such as price momentum and volatility do not enter the number; they are shown separately in the detail view.
What is the price target for Imerys S.A (IMYSF)?
Our model-based price target is the fair value of $9.55 (as of Sep 24, 2026) from 14 valuation models. Cautious scenario $9.55, optimistic scenario $23.44. It is a calculation from audited fundamentals, not an analyst target.
What is the Imerys S.A stock forecast for 2026?
Our models put fair value at $9.55, about −63% upside versus the last price from Sep 25, 2026 of $25.59 (overvalued). Cautious scenario $9.55, optimistic scenario $23.44. The calculation is refreshed regularly with new filings.
What is the revenue of Imerys S.A (IMYSF)?
Imerys S.A reported trailing-twelve-month revenue of about €3.3B (latest available figure, as of Sep 24, 2026).
What growth is priced into Imerys S.A (IMYSF)?
For today's price to be fair in a discounted-cash-flow model, Imerys S.A would have to grow free cash flow by +16.3 % per year for five years (discount rate 9.1 %, then slowing evenly to 2 % perpetual growth by year ten). Over the last 5 years revenue grew -2.3 % per year. As of Sep 24, 2026.
What discount rate (WACC) does the fair value of IMYSF use?
Our models discount Imerys S.A at 9.1 %: a base by market capitalisation (mid), damped by beta 0.74, country premium for USA. The same rate applies in all 26 models.
What is a reverse DCF?
A reverse DCF turns the usual calculation around. Instead of deriving a value from assumptions, it takes today's price as given and asks: what free-cash-flow growth would a company have to deliver for exactly this price to be fair? The result is not a forecast but the expectation already priced in. For Imerys S.A that is +16.3 % per year a year over ten years, using the same discount rate (9.1 %) and the same formula as our fair value.
How much growth has Imerys S.A (IMYSF) delivered so far?
Over the past 5 years revenue at Imerys S.A grew -2.3 % a year. The price currently implies +16.3 % per year free-cash-flow growth a year. Comparing the two shows how much confidence is in the price: if it demands more than has been delivered, the business has to accelerate for the maths to work.
How fast is the sector of Imerys S.A (IMYSF) growing?
The median revenue growth in the sector is +7.6 % a year. That is the yardstick for the growth priced into Imerys S.A (+16.3 % per year a year): it shows whether the expectation is within the usual range or beyond it.
What is the free cash flow yield of Imerys S.A (IMYSF)?
The free-cash-flow yield on the price is 5.82 %: that much free cash flow Imerys S.A produces per unit of market value. When it exceeds the discount rate of our models (9.1 %), the business already earns more than its cost of capital demands, and the price needs little additional growth.
What is the intrinsic value of Imerys S.A (IMYSF)?
Intrinsic value and fair value mean the same thing: what the business is worth on its numbers, independent of the share price. For Imerys S.A it is $9.55 per share (as of Sep 24, 2026), against a price of $25.59. It is the blended result of 14 valuation models (cash flow, earnings, asset, dividend).
Is Imerys S.A stock overvalued or undervalued in 2026?
As of Sep 24, 2026, IMYSF trades above its calculated fair value: price $25.59, fair value $9.55, a gap of about −63% (overvalued). The calculation is refreshed with each new quarterly report, so the verdict can change during the year.
Is fair value the same as the market price of IMYSF?
No. The price is what the market pays today ($25.59); the fair value is what the company's own numbers justify ($9.55). For Imerys S.A the two are $16.04 per share apart. That gap is exactly why we show both numbers side by side.
How much is Imerys S.A worth?
The market values Imerys S.A at about $2.2B (market capitalisation, as of Sep 24, 2026). Per share that is $25.59; our models calculate a fair value of $9.55 per share.
What do the bullish and bearish scenarios say about IMYSF?
Our models span a range for Imerys S.A: cautious scenario $9.55, base $9.55, optimistic $23.44 per share (as of Sep 24, 2026, price $25.59). The range comes from different growth and margin assumptions, not from analyst opinions.
Which stocks are comparable to Imerys S.A?
From the same area (Basic Materials) we also value Linde plc, The Sherwin-Williams Company, Ecolab Inc, Air Products and Chemicals, Inc, among others. Each of them has its own fair-value calculation on this site using the same models, so the comparison is like for like.
Is Imerys S.A stock attractive at the current price?
The data as of Sep 24, 2026: price $25.59, calculated fair value $9.55 (−63%), Quality Score 43/100, from 14 models. Whether that fits your horizon and risk tolerance is your call. We provide the calculation, not investment advice.
How is the fair value of IMYSF calculated?
We run Imerys S.A through 14 models from four families: discounted cash flow, earnings models, asset and balance-sheet models, and dividend models. Every model gets the same audited fundamentals; the result is the weighted average of $9.55, with the spread shown as a cautious and an optimistic scenario.
Is it still worth investing in stocks now?
The global stock market currently sits 14.5 % above its aggregate fair value. Imerys S.A itself currently trades above fair value. An expensive market is no reason to stay out and no reason to buy everything at once: keep a broad savings plan running, buy single stocks only with money you can do without, and hold part of your money liquid while the market is high. The full picture including sectors is on is it worth investing now.
What is the share price of Imerys S.A (IMYSF)?
The latest price we hold is from Sep 25, 2026 and stands at $25.59. Our model-based fair value is $9.55, about −63% upside (overvalued). We carry closing prices from our data provider, not a live tick.
What should I pay attention to with Imerys S.A right now?
The price sits above even our optimistic bull case ($23.44). The favourable scenario is already priced in. Weak quality (43/100) and above fair value at the same time, the margin of safety is missing on both counts. A fairly wide model range ($9.55 to $23.44) leaves room in how you read the outcome.
Key figures of Imerys S.A
How large is the market capitalisation of Imerys S.A (IMYSF)?
The market capitalisation of Imerys S.A is $2.2B. The stock-market value of the whole company: share price times number of shares. It is what the market asks for the entire business today.
What is the P/E ratio of Imerys S.A (IMYSF)?
The price-to-earnings ratio of Imerys S.A is 12.9. Price to earnings: how many years of current profit you pay for the stock. A P/E of 10 means ten years of profit.
What is the P/S ratio of Imerys S.A (IMYSF)?
The price-to-sales ratio of Imerys S.A is 0.68 (last twelve months). Price to sales: market value relative to yearly revenue. Useful when profit is thin or distorted.
What are the earnings per share of Imerys S.A (IMYSF)?
Earnings per share at Imerys S.A are $1.99 (price ÷ EPS = P/E 12.9). Earnings per share over the last twelve months: total profit spread across every single share.
What is the net margin of Imerys S.A (IMYSF)?
The net margin of Imerys S.A is −12.1% (fiscal year 2025). How much of every unit of revenue ends up as profit. 10% means 10 cents of profit per dollar of sales.
What is the return on equity of Imerys S.A (IMYSF)?
The return on equity (ROE) of Imerys S.A is −13.9% (last twelve months). Profit relative to shareholders' equity, how efficiently the company works with its owners' money.
What is the EBIT return on assets of Imerys S.A (IMYSF)?
On an EBIT basis the return on assets of Imerys S.A is 4.3% (avg 5y). Operating profit (EBIT) relative to everything the company owns, as a multi-year average. It describes the business model rather than one good or bad year.
What is the operating margin of Imerys S.A (IMYSF)?
The operating margin of Imerys S.A is 5.5% (last twelve months). Profit from the core business (before interest and taxes) relative to revenue.
How fast is revenue growing at Imerys S.A (IMYSF)?
Revenue at Imerys S.A is growing −4.1% versus a year earlier (3y avg −7.5%). How much revenue grew versus a year earlier (YoY). The 3-year average next to it puts the single year in context.
How fast are earnings growing at Imerys S.A (IMYSF)?
Earnings per share at Imerys S.A are growing −34.7% versus a year earlier. How much earnings per share grew versus a year earlier.
How much net debt does Imerys S.A (IMYSF) carry?
The net debt of Imerys S.A is €1.6B (fiscal year 2025, ≈ 14.4 yrs of FCF). Debt minus cash on hand. The note shows how many years of free cash flow could in theory pay it off.
Free · no account needed
Continue in the live analysis
Fair value and trend for 35,000+ stocks, watchlist, comparison and the diversification check. You can also try 14 days of Pro there, no card.
Open the live analysis →Zero risk: nothing is ever charged. Your watchlist is yours, with or without an account.